What is the equivalent dose conversion of Adderall (amphetamine/dextroamphetamine) 30mg Extended Release (XR) to Vyvanse (lisdexamfetamine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adderall XR 30mg to Vyvanse Conversion

The equivalent dose conversion from Adderall XR 30mg to Vyvanse is 50mg, based on the pharmacologic principle that lisdexamfetamine (Vyvanse) is a prodrug that converts to dextroamphetamine at approximately a 1.5:1 to 2:1 ratio by weight.

Conversion Rationale

The conversion is based on the following pharmacologic considerations:

  • Vyvanse (lisdexamfetamine) is a prodrug that is enzymatically converted to dextroamphetamine in the blood after oral administration 1, 2
  • Adderall XR contains 75% dextroamphetamine salts and 25% levoamphetamine salts, meaning 30mg Adderall XR delivers approximately 22.5mg of dextroamphetamine equivalents 3
  • The molecular weight difference between lisdexamfetamine and dextroamphetamine means that approximately 50mg of lisdexamfetamine yields roughly 30mg of active dextroamphetamine 1

Practical Conversion Algorithm

When switching from Adderall XR 30mg to Vyvanse:

  • Start with Vyvanse 50mg once daily in the morning 4
  • This represents a conservative 1:1.67 conversion ratio that accounts for the prodrug metabolism
  • Morning administration is critical to minimize sleep disturbances 5, 6
  • Allow at least one week to evaluate response before making any dose adjustments 5, 7

Titration After Conversion

If symptom control is inadequate after one week on Vyvanse 50mg:

  • Increase by 10mg weekly increments up to the maximum of 70mg daily 4
  • Do not exceed 70mg daily, as this is the FDA-approved maximum dose 4
  • If 70mg provides inadequate benefit, switch to an alternative medication rather than exceeding the maximum dose 5, 7

Monitoring Requirements Post-Conversion

After switching medications, systematic monitoring is essential:

  • Assess blood pressure and pulse at the first follow-up visit after conversion 5, 7
  • Evaluate target ADHD symptoms using standardized rating scales 7
  • Monitor for common side effects including decreased appetite, insomnia, upper abdominal pain, headache, and irritability 1, 8
  • Weigh the patient at each visit to detect appetite suppression 5, 7

Clinical Advantages of This Conversion

The switch from Adderall XR to Vyvanse offers several benefits:

  • Once-daily dosing with duration of effect up to 13-14 hours, potentially longer than Adderall XR 8, 9
  • Lower abuse potential compared to immediate-release amphetamine formulations due to the prodrug mechanism 1
  • More consistent pharmacokinetics with linear dose-response relationship 1

Common Pitfalls to Avoid

When performing this conversion, avoid these errors:

  • Do not use a simple 1:1 conversion (30mg Adderall XR to 30mg Vyvanse), as this will likely result in underdosing 1
  • Do not start at Vyvanse 70mg even though the patient was on a moderate Adderall XR dose—allow for titration to assess tolerability 5, 6
  • Do not make dose adjustments more frequently than weekly, as insufficient time between increases prevents proper evaluation of response 5, 7
  • Do not administer Vyvanse in the afternoon or evening, as this will cause insomnia 5, 6

Expected Timeline for Efficacy

After conversion to Vyvanse 50mg:

  • Therapeutic effects should be evident within 1.5 hours of administration and maintained through 13 hours post-dose 8
  • Full clinical response assessment requires at least one week at the new dose 5, 7
  • If switching due to inadequate duration of effect with Adderall XR, patients should notice extended afternoon and early evening symptom control 8, 9

References

Research

Adderall® (amphetamine-dextroamphetamine) toxicity.

Topics in companion animal medicine, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Adderall Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Adderall XR Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Adderall Dosing Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.